Evidence map›Paper›PMID 39945266›Full record

ArticleMicroRNA (Shariqah, United Arab Emirates)2025

Bone Marrow Mesenchymal Stem Cells Overexpressing MicroRNA-126 to Treat Critical Limb Ischemia.

Pegah Nammian, Seyedeh-Leili Asadi-Yousefabad, Seyyed Sajad Daneshi, Jafar Fallahi, Sahar Khajeh, Seyed Mohammad Bagher Tabei, Vahid Razban

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in MicroRNA (Shariqah, United Arab Emirates), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Pegah NammianDepartment of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyedeh-Leili Asadi-YousefabadDepartment of Molecular Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Seyyed Sajad DaneshiPostdoctoral Researcher, Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Jafar FallahiDepartment of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Sahar KhajehBone and Joint Disease Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Mohammad Bagher TabeiDepartment of Genetics, Shiraz University of Medical Science, Shiraz, Iran.
Vahid RazbanDepartment of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCritical limb ischemia (CLI) is considered the most severe form of peripheral artery disease (PAD). Nowadays, using stem cells such as mesenchymal stem cells (MSCs) to induce angiogenesis seems like a promising method for CLI therapy. Among the many factors that affect the angiogenesis process, microRNA-126 has an important role.

objectiveThe goal of this study was to increase the angiogenic potential of bone marrow mesenchymal stem cells (BMSCs) via using microRNA-126.

methodsBMSCs were isolated from male C57BL/6 inbred mice. CLI model was created by femoral artery ligation on C57BL/6 mice. Animals were allocated to control, BMSCs, miR-126, and BMSCsmiR-126 groups, and a defined number of the cells and virus were injected 24 h after surgery. Then, wound-healing assay, functional tests, real-time PCR, histopathological evaluation, and donor cell survival were performed.

resultsResults showed that BMSCs and miR-126 groups had a positive effect on angiogenesis. BMSCs miR-126 group had a significant effect on functional improvements, endothelial cell migration, neovascularization, and muscle restructures. In vivo evaluation showed that miR-126 could increase BMSCs survival and paracrine secretion of angiogenic factors such as VEGF and led to remarkable functional improvements and neovascularization in ischemic tissues.

conclusionIt can be concluded that the combination uses of BMSCs and miR-126 lead to more effective recovery from ischemic damage compared with using them alone. MiR-126 can be used as a strong modifier to reinforce the angiogenic potential, paracrine secretion, and survival of the BMSCs.

Indexed as

IschemiaMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMicroRNAsAnimalsCell MovementDisease Models, AnimalMaleMiceMice, Inbred C57BLNeovascularization, PhysiologicMicroRNAsMIRN126 microRNA, mouseAngiogenesisBMSCscritical limb ischemia.gene therapyMicroRNA-126stem cell therapy

Identifiers

PMID39945266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.